OMCL Stock Recent News

The average of price targets set by Wall Street analysts indicates a potential upside of 29% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

OMCL returns to year-over-year revenue growth in the fourth quarter of 2024.

Omnicell, Inc. (NASDAQ:OMCL ) Q4 2024 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants Kathleen Nemeth - Senior Vice President, Investor Relations Randall Lipps - Founder, Chairman, President and Chief Executive Officer Nchacha Etta - Executive Vice President and Chief Financial Officer Conference Call Participants Allen Lutz - Bank of America Jessica Datson - Piper Sandler Matt Hewitt - Craig-Hallum Capital Group Scott Schoenhaus - KeyBanc Capital Markets Stan Berenshteyn - Wells Fargo David Larsen - BTIG Gene Mannheimer - Freedom Capital Markets Operator Thank you for standing by. My name is Kathleen and I will be your conference operator today.

Omnicell (OMCL) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.33 per share a year ago.

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results.

OMCL stays on investors' radar due to the strong performance of the Advanced Services portfolio.

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Enovis, Omnicell and Phreesia have been highlighted in this Industry Outlook article.

Zacks Medical Info Systems industry stocks like Enovis, Omnicell and Phreesia are expected to gain from the GenAI wave.

Doximity, Omnicell, Embecta, Cencora and EDOC are included in this Analyst Blog.